35 results about "Radionuclide therapy" patented technology

The invention provides a microdosimetry-based evaluation method for a targeted alpha radionuclide treatment biological effective dose, and the method comprises the steps: carrying out the integration of a time activity curve of alpha radionuclide in an organ, obtaining the cumulative activity, and calculating the physical absorbed dose and dose rate of the organ through Monte Carlo simulation; based on micro-dose Monte Carlo simulation, constructing a micro-dose spectrum of the alpha radionuclide to obtain saturation correction dose average linear energy for representing radiation quality; obtaining biological effect parameters of the alpha radionuclide by fitting saturation correction dose average line energy and cell experiment data by using a micro-dose kinetic model; and evaluating the biological effective dose of the target organ in combination with the physical absorbed dose, the dose rate and the biological effect parameter. According to the method, the problem that a biological effective dose evaluation method is lacked in dose evaluation of targeted alpha radionuclide treatment is solved.

The invention provides a target Her2 nuclide probe as well as a preparation method and application thereof, and relates to the technical field of nuclide probes. The target Her2 nuclide probe comprises a compound which is labeled by radionuclide and is shown in a formula I. The target Her2 nuclide probe can be used as a diagnosis and treatment reagent in human or animal Her2 protein high expression lesions, and is especially used as a tumor imaging agent and a radionuclide treatment drug. In animal experiments, the tumor / muscle ratio of the radioactive complex is high, and the radioactive complex has a good application prospect. And the formula I of the # imgabs0 # is shown in the specification.

The invention proposes a voxel-level dose distribution prediction method, and the method comprises the steps: obtaining a detection image of a target object when each tracer is independently introduced under the condition that a plurality of tracers are independently introduced into the target object; performing image standardization processing on the detection image corresponding to each tracer agent to obtain a standardized image corresponding to each tracer agent; and taking the standardized images corresponding to the various tracers as input information of a deep learning model, and determining a comprehensive three-dimensional dose prediction result of the target object under the various tracers through the deep learning model. According to the technical scheme, the accuracy of dose prediction in nuclide therapy is improved, full-link automation from image acquisition to dose planning is realized, the generated dose distribution not only meets the clinical requirement of precise coverage of a target region, but also conforms to the radiotherapy principle of normal tissue protection, and reliable technical support is provided for personalized precise radiotherapy.

The invention relates to the technical field of dosimetry, in particular to a rapid dose evaluation method and device for individualized targeted radionuclide treatment.The method comprises the steps that labeled nuclides, drug ligands and image data of a patient are obtained, and corresponding standard S values are selected according to the labeled nuclides and the drug ligands; the method comprises the following steps: segmenting first-time-phase CT image data to obtain a segmentation mask of a target organ, calculating an individualized S value based on the segmentation mask, generating an individualized voxel model, registering the SPECT image data and the CT image data to obtain organ-level source item parameters and voxel-level source item parameters, and calculating an individualized S value based on the individualized voxel model to obtain an organ-level source item parameter and a voxel-level source item parameter; and according to the organ-level source item parameter and the voxel-level source item parameter, respectively obtaining an organ-level dose evaluation result and a voxel-level dose evaluation result, and comprehensively evaluating source target organ dose distribution. Therefore, the problems that the dose conversion coefficient lacks calibration, the voxel model is difficult to balance the calculation speed and precision and the like are solved, errors caused by individualized differences are reduced, and the calculation accuracy and speed are guaranteed.

The invention relates to the technical field of nuclide probes, and discloses a targeted PARP nuclide probe and a preparation method and application thereof, and the targeted PARP nuclide probe comprises a radionuclide labeled compound as shown in formula I; the targeted PARP nuclide probe provided by the invention can be used as a diagnosis and treatment reagent to be applied to tumors with high PARP protein expression in human or animal bodies, and is especially suitable for tumor imaging and radionuclide treatment; animal experiments show that the nuclide probe has a high tumor / muscle uptake ratio and shows good application potential. Formula I.

This invention relates to a portable on-site detection device and method for Lu-177 radionuclide activity. The detection device includes a gamma detection assembly and a circuit board installed within a housing. The gamma detection assembly comprises several pieces, each housing a gamma detection module. The space formed by the gamma detection assemblies serves as a sample chamber, with a central slot for holding a Lu-177 carrier bottle. The gamma detection module employs a combination structure of a GAGG:Ce scintillator and a silicon photomultiplier tube (SiPM). The circuit board houses a connection module between the circuit board and the gamma detection assembly, a power conversion module, a signal summing circuit for the gamma detection assembly, a digital multichannel module, and a data analysis and transmission module. The testing method includes five steps, including device initialization. The beneficial effects are that it provides technical support for accurate pre-administration dose verification of Lu-177, ensuring medication safety for patients undergoing radionuclide therapy and improving the quality of clinical nuclear medicine treatment.

The present invention relates to application of 64Cu in radionuclide-based cancer therapy in humans. More specifically, the invention relates to 64Cu labeled conjugates for use in the treatment of cancer patients including 64Cu labelled Integrin αVβ3 binding conjugates, such as [64Cu]NODAGA-E[c(RGDyK)]2.

A method for preparing a radioactive in-situ vaccine includes the following steps: First, prepare calcium carbonate microsphere powder with calcium chloride and sodium carbonate solutions, then prepare mesoporous hydroxyapatite with a phosphate solution and the calcium carbonate microsphere powder, and then add a manganese salt to obtain manganese-doped hydroxyapatite microspheres; then label with a radionuclide to obtain radionuclide-labeled manganese-doped hydroxyapatite microspheres. The radionuclide therapy adopted in the present invention can well confine the rays to the tumor site, and can avoid systemic reactions while continuously irradiating the tumor; the selected manganese adjuvant, as an essential trace element for the human body, is safer, cheaper and easier to obtain. On the other hand, the manganese doped in the microspheres themselves can activate the immune system after release, and in addition, the special mesoporous structure of the microspheres can achieve efficient capture of tumor antigens, maintain a high concentration of antigen in the tumor site, continuously activate the immune system, produce an anti-tumor effect, and achieve universal tumor treatment.

A pharmaceutical composition for targeted radionuclide therapy comprising a plurality of nanostructures. Each respective nanostructure may comprise a hydrophilic inner cavity and an outer shell of PEG. The hydrophilic inner cavity may comprise a colloidal solution of Lu-177 DOTATAE and a plurality of high-atomic-number nanoparticles selected from a group consisting of gold nanoparticles, platinum nanoparticles and tantalum nanoparticles with a maximum diameter of 1 to 20 nm in a aqueous medium with a ratio (Lu-177 DOTATE: the plurality of high- atomic-number nanoparticles) of 1: 50-60. The outer shell of PEG may have a surface charge between -0.1 and -0.3 mV. The plurality of high-atomic-number nanoparticles may have a diameter of 20 nm. Each respective nanostructure may have a diameter between 50 and 200 nm. Each respective nanostructure may have a diameter of 150 nm. The aqueous medium may be selected from a group consisting water and acetone.

The invention relates to the technical field of nuclide probes, and discloses a COX-2 targeting nuclide probe as well as a preparation method and application thereof, and the COX-2 targeting nuclide probe comprises a radionuclide labeled compound as shown in a formula I; the targeting COX-2 nuclide probe provided by the invention can be used as a diagnosis and treatment reagent to be applied to tumors with high COX-2 protein expression in human or animal bodies, and is especially suitable for tumor imaging and radionuclide treatment; animal experiments show that the nuclide probe has a high tumor / muscle uptake ratio and shows good application potential. Formula I.

The present invention provides a Her2-targeted nuclide probe and a preparation method and application thereof, and relates to the technical field of nuclide probes. The Her2-targeted nuclide probe comprises a compound shown in formula I labeled with a radionuclide. The Her2-targeted nuclide probe of the present invention can be used as a diagnostic and therapeutic agent in lesions with high expression of Her2 protein in humans or animals, in particular as a tumor imaging agent and a radionuclide therapeutic drug. In animal experiments, the radioactive complex of the present invention has a high tumor / muscle ratio and has good application prospects. Formula I.

The present invention relates to the fields of high molecular heterocyclic compounds and nuclear medicine imaging technology, and particularly relates to a PET probe obtained by coupling an SSTR agonist and an inhibitor, and a preparation method and application thereof. The PET molecular probe comprises a targeting molecule obtained by coupling an SSTR agonist and an inhibitor, a radioisotope, and a linker, and the linker connects the targeting molecule and the radioisotope. The heterodimer obtained by coupling the SSTR agonist and the inhibitor can improve the PET detection sensitivity by increasing the binding affinity with the target through a synergistic effect; has higher specificity and can specifically and efficiently target SSTR for in vivo imaging in a variety of tumor microenvironments; not only makes the distribution of the radioligand more uniform, but also can effectively improve the clinical effect of radionuclide therapy after labeling with therapeutic radionuclides such as <supgt;177< / supgt;Lu. Compared with the prior art, the molecular probe has stronger affinity, higher stability and higher target-to-background ratio; meanwhile, the preparation method of the PET molecular probe is simple and stable, and has good market promotion and application prospects.

The invention relates to the technical field of ray therapy, and discloses a radionuclide therapeutic dose calculation system, which is used for importing a quantitative PET / CT (positron emission tomography / computed tomography) image of a patient before radionuclide therapy and a quantitative SPECT / CT image acquired after the therapy. According to the quantitative SPECT image, the radionuclide type, the drug name, the image acquisition time, the height, the weight and the radionuclide distribution condition in the body of a patient are obtained, and the DICOM analysis module reads information contained in a quantitative SPECT image tag. According to the method, the individualization of the dose calculation phantom is realized; the individualized computer phantom of the patient can be quickly generated according to the CT image of the patient; and the anatomical characteristics of the patient are accurately described to the greatest extent. The method does not depend on any standard reference body model, solves the problem that the specificity of the body shape and the anatomical structure of the patient is difficult to consider by adopting the standard reference body model in the prior art, and improves the accuracy of dose calculation.

The application discloses a novel radionuclide therapeutic drug targeting nucleolus DDX24 helicase and a preparation method and application thereof. 64 The Cu-DOTA-TDP-2 has good tumor targeting uptake specificity, and is expected to provide a precise molecular imaging method for esophageal squamous cell carcinoma and other DDX24 high-expression malignant tumors; the novel radionuclide targeted drug 177 The Lu-DOTA-TDP-2 has high radiochemical yield and specific activity, good chemical stability, high affinity for DDX24 helicase, and a simple and easy-to-operate preparation method, and can be used for the treatment of DDX24 high-expression malignant tumors; the novel radionuclide targeted drug 177 The Lu-DOTA-TDP-2 has excellent biological safety performance and good tumor inhibition effect in esophageal squamous cell carcinoma and other DDX24 high-expression malignant tumors.

The invention provides a radiopharmaceutical and application thereof, and relates to the technical field of nuclear medicine, the radiopharmaceutical provided by the invention can be used as an integrin alpha4beta7 imaging agent, and imaging diagnosis can be carried out on focuses of diseases (such as inflammatory bowel diseases or tumor diseases) related to positive expression of integrin alpha4beta7 by utilizing a PET imaging technology of nuclear medicine. A chelating part in the integrin alpha4beta7 radiopharmaceutical can be replaced by NOTA chelating agents, NODAGA chelating agents, DOTAGA chelating agents, THP chelating agents and TRAP chelating agents, and the integrin alpha4beta7 radiopharmaceutical can be used for labeling < 68 > Ga metal nuclides, < 61 > Cu metal nuclides, < 64 > Cu metal nuclides and < 177 > Lu metal nuclides, so that PET imaging and nuclide treatment of various nuclides are further realized.

The utility model relates to a radionuclide treatment patient urine collection and temporary storage device which comprises a funnel-type collector arranged on a portable pedestal pan, a urine temporary storage tank is arranged below the funnel-type collector, the urine temporary storage tank is composed of an inner barrel body and an outer protective sleeve, a funnel opening in the lower end of the funnel-type collector can be inserted into the inner barrel body, and the outer protective sleeve can be inserted into the funnel opening in the lower end of the funnel-type collector. Urine of a patient subjected to nuclide treatment is collected in the inner barrel body, protection of different radionuclides in the urine is achieved through the outer protection sleeve, the upper face and the lower face of the outer protection sleeve are provided with structures capable of being connected and positioned respectively, and multiple urine temporary storage tanks can be stacked up and down in multiple layers. The temporary storage tank is suitable for temporarily storing treatment nuclides emitting pure beta particles, such as 90Y, or treatment nuclides emitting beta particles accompanied by low-energy gamma rays, such as 177Lu and 161Tb. According to the utility model, a new treatment project can be carried out under the environment-friendly condition for a medical unit for developing radionuclide tumor treatment when the capacity of the decay pool is insufficient or no decay pool exists, so that the number of treated patients is increased.

The present disclosure relates to combination treatments for cancer. Specifically, the present disclosures relates to combination treatment of neuroendocrine tumors with an inhibitor of estrogen signaling or a retinoid, and radiation therapy or targeted radionuclide therapy.

This invention provides a c-MET-targeting nuclide probe, its preparation method, and its applications, relating to the field of nuclide probe technology. The c-MET-targeting nuclide probe comprises a compound of formula I labeled with a radionuclide. The c-MET-targeting nuclide probe of this invention can be used as a diagnostic and therapeutic agent in human or animal lesions with high c-MET protein expression, particularly as a tumor imaging agent and a radionuclide therapeutic drug.

The invention relates to an acyclic chelating agent as well as a preparation method and application thereof. The acyclic chelating agent is a compound as shown in a formula I or a pharmaceutically acceptable salt of the compound as shown in the formula I. Compared with a common macrocyclic chelating agent, the non-cyclic chelating agent disclosed by the invention can be used for rapidly and efficiently marking radioactive metal nuclides under mild conditions, and is used for imaging such as PET (Polyethylene Terephthalate), SPECT (Single Photon Emission Computed Tomography) and MRI (Magnetic Resonance Imaging) or radionuclide treatment application research after being chelated with the radionuclides.

A compound of formula (I) and its use in therapeutic and diagnostic methods such as radionuclide therapy or nuclear diagnostic imaging.

The present disclosure relates to new folate-conjugates comprising a 5-methyltetrahydro-folate, a radiometal chelator optionally coordinating a radiometal M, and the albumin binder 5-(p-iodophenyl)pentanoate, and further provides uses of such conjugates and / or pharmaceutical compositions thereof in diagnostic imaging, radionuclide therapy or theragnostic applications.

This invention relates to a biomimetic delivery system co-loaded with a radionuclide and a KDM5B degrading agent, its preparation method, and its application. The biomimetic delivery system includes liposomes, KDM5B degrading agent CMATACs encapsulated within the liposomes, and a radionuclide labeled on the surface of the liposomes. 177 Lu, erythrocyte membrane vesicles encapsulating the liposomes, and tumor homing peptide CREKA modified on the surface of the liposomes. Compared with the prior art, this invention achieves for the first time the synergistic delivery of "epigenetic regulation and targeted radionuclide therapy", and the prepared biomimetic delivery system has excellent in vivo anti-tumor effects and biosafety.

The present disclosure provides a high-energy, low toxicity radiopharmaceutical composition comprising actinium that performs as an anti-tumor agent for targeted radionuclide therapy. The radiopharmaceutical composition disclosed herein has a short physical half-life of about 9.9 days and produces low toxicity profiles.

The embodiment of the invention relates to the technical field of PET imaging, and discloses a preparation method of a melanoma imaging targeting molecule, which comprises the following steps: synthesizing a chelating agent NOTA derivative monomer; synthesizing a methylene blue derivative monomer; the preparation method comprises the following steps: mixing a chelating agent NOTA derivative monomer and a methylene blue derivative monomer, carrying out acid-amine condensation or click reaction on the two monomers, and hydrolyzing to obtain the melanoma imaging targeting molecule. The melanoma imaging targeting molecule has good biological characteristics and tumor targeting imaging capability in a malignant melanoma xenotransplantation model, and can overcome the defects of low diagnosis sensitivity and nuclide treatment deficiency. In addition, the invention also provides a melanoma imaging targeting molecule, an imaging agent comprising the melanoma imaging targeting molecule and application of the imaging agent in the field of PET imaging.

The group of inventions relates to chemistry and the pharmaceutical industry, and more particularly to the field of radiopharmaceutical preparation. The group of inventions includes: a lyophilizate based on prostate-specific membrane antigen (PSMA) ligands for the preparation of a radiopharmaceutical composition, said lyophilizate containing PSMA I&T precursor, sodium acetate, gentisic acid and mannitol; a radiopharmaceutical composition in the form of an injectable solution for the treatment of prostate cancer, having a pH of 4.0-6.3 and containing the active substance 177Lu in the form of a 177Lu-PSMA I&T complex with a radioactivity concentration of 6000 MBq / ml, as well as sodium acetate, gentisic acid and mannitol; and a method for preparing said radiopharmaceutical composition from the proposed lyophilizate. The group of inventions expands the existing range of effective and safe radiopharmaceuticals for the targeted radionuclide therapy of castration-resistant prostate cancer.

The invention provides a targeting c-MET nuclide probe as well as a preparation method and application thereof, and relates to the technical field of nuclide probes. The targeting c-MET nuclide probe comprises a radionuclide labeled compound as shown in a formula I. The targeting c-MET nuclide probe can be used as a diagnosis and treatment reagent in a human or animal c-MET protein high expression focus, and is especially used as a tumor imaging agent and a radionuclide treatment drug.

In the treatment of patients with tumors (especially malignant tumors), the substances phenoxythiamine (B-OT) and / or oxothiamine (OT) are administered as active ingredients concurrently with ongoing radionuclide therapy (RNT) (particularly radioimmunotherapy (RIT) and / or radiopeptide or radioligand or radiopeptide ligand therapy (RLT)). B-OT and / or OT administration is cyclical, meaning that dosing phases of B-OT and / or OT (“B-OT / OT dosing cycles”) alternate with treatment intervals (dosing intervals). During each B-OT / OT dosing cycle, B-OT and / or OT are administered at a predetermined dose (mg / kg patient body weight) for one or more consecutive days. This is followed by a treatment interval during which neither B-OT nor OT is administered, before the next B-OT / OT dosing cycle begins.

The invention relates to the technical field of nuclide probes, and discloses an alpha v beta 3 targeted polypeptide nuclide probe and a preparation method and application thereof, and the alpha v beta 3 targeted polypeptide nuclide probe comprises a radionuclide labeled compound as shown in a formula I. The targeted alpha v beta 3 polypeptide nuclide probe provided by the invention can be used as a diagnosis and treatment reagent to be applied to tumors with high expression of alpha v beta 3 protein in human or animal bodies, and is especially suitable for tumor imaging and radionuclide treatment; animal experiments show that the nuclide probe has a high tumor / muscle uptake ratio and shows good application potential. Formula I.

This invention relates to the fields of medical device manufacturing, radionuclide therapy, and automated control technology, specifically to an automated dressing manufacturing method and equipment, comprising: acquiring a skin scar image; segmenting and generating a target area feature map using an image recognition model; generating a cutting path based on the image and automatically cutting a carrier material to form a substrate matching the shape of the scar; quantitatively applying phosphorus-32 solution to the substrate according to preset activity parameters; and post-processing to produce a phosphorus-32 dressing. This invention accurately reproduces the scar contour through image recognition and automatic cutting, achieving a high degree of morphological matching and improving irradiation accuracy; parameterized application ensures uniform dosage, improving treatment safety and efficacy stability; and the fully automated process shortens the preparation cycle, reduces manual intervention, efficiently meets clinical needs, and simultaneously reduces the risk of radioactive operation, enhancing radiation safety.

This invention relates to a method for preparing and applying a nanoprobe for multimodal imaging and synergistic therapy, belonging to the field of bioprobe technology. The method includes: loading the acoustic sensitizer MnTTP and the hypoxia-activating drug TPZ onto PLGA via an emulsion-solvent evaporation method, modifying it to an aqueous phase using PVA, using dopamine hydrochloride to increase biocompatibility, obtaining the nanoprobe TMP@D, and then... (The sentence is incomplete in the original text). 131 I-labeling on TMP@D yields radionuclide-loaded nanoprobes. 131 I-TMP@D. 131 I-TMP@D passively targets and enters tumor cells, enabling synergistic treatment of malignant hypoxic tumors by combining MR and SPECT multimodal imaging with radionuclide therapy, sonodynamic therapy, and hypoxia-activated chemotherapy.